Foghorn Therapeutics Inc
FHTX
Get informed when a big investor buys or sells
+ FollowMarket Cap$117.43M
Close$
Share Statistics
| Market cap | $117.43 Million |
|---|---|
| Enterprise Value | $129.04 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.18 |
| Beta | 3.01 |
| Outstanding Shares | 70,629,419 |
Return
| Return on Equity | 79.69% |
|---|---|
| Return on Assets | -31.75% |
| Return on Invested Capital | -43.75% |
Valuation & Multiples
| P/E Ratio | -2.02 |
|---|---|
| PEG | 3.37 |
| Price to Sales | - |
| Price to Book Ratio | -0.95 |
| Enterprise Value to Revenue | 3.51 |
| Enterprise Value to EBIT | -1.93 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0.62 |
| Debt to Equity | -0.98 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 6, 2026
EPS Estimate
$-0.24
Average shareholder expectationRevenue Estimate
$6.81 M
Average shareholder expectationNext Earnings Call
Expected Date
November 4, 2026
EPS Estimate
$-0.23
Average shareholder expectationRevenue Estimate
$6.39 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 63.76%▼ 0.14% |
|---|---|
| Total Invested | $219.77M▲ 3.45% |
| Investors Holding | 105▲ 1.00% |
ESG Score
No data
About Foghorn Therapeutics Inc
95 employeesFoghorn Therapeutics is pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, an untapped opportunity for therapeutic intervention. The ...